Introduction
Treating pain has been always challenging, especially when it becomes chronic in nature. Current drugs (e.g. opioid drugs) cannot treat this problem effectively. In addition, constant use of these drugs has deadly side effects including drowsiness and mental clouding, nausea and emesis, and constipation [1] . Development of analgesic tolerance and hyperalgesia in many patients as the results of taking these drugs are also a serious concern. Overexpression of substance P and its receptor has been observed during prolonged pain states. Studies revealed that co-administration of cocktails of drugs containing µ/δ opioid agonist and NK1 antagonist can provide better analgesic effects in rat model while reducing side effects [2] [3] [4] . Herein, we report design, synthesis and SARs of few multifunctional ligands having µ/δ opioid agonist (µ-preferring) and NK1 antagonist activities. The detail of this study has already been communicated to J. Med. Chem. for publication [5] . We anticipate that these ligands will show better analgesia while reducing the adverse side effects. Our drug design principle is based on overlapping and adjacent pharmacophores ( Figure 1 ) and we considered our previously published µ-selective (binding) ligand TY012 (H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bn(3ʹ,5ʹ-(CF3)2)) [6] . 
Synthesis of the ligands
Linear peptides [Boc-Tyr( t Bu)-(AA)n-Pro-Leu-Trp(Boc)-OH] were synthesized using Fmoc/ t Bu solid phase chemistry on a 2-chlorotrityl resin. The C-terminal carboxylic acid was amidated in solution phase. Removal of all protecting groups followed by purification afforded the pure ligands required for biological study. The ligands we designed and synthesized are given in Figure 2 .
Fig. 2. Structures of our multifunctional ligands.

Results and Discussion
The present study was designed to synthesized µ-selective ligands while maintaining the antagonist activity at NK1 receptor. To achieve our goal we considered our previously published µ-selective (binding) ligand TY012 [6] and structural modification was conducted in the opioid pharmacophore moiety. We introduced Dmt at the 1 st position, and NMe-Phe or halogenated-Phe at the 4 th position (Figure 2 ) to achieve our desired selectivity with high potency at all receptors. AKG117 having NMe-Phe at 4 th position showed a small increase in μ-agonist activity (Table 1) . AKG115 having Dmt at the 1 st position and NMe-Phe at the 4 th position showed selectivity (both binding and functional) for MOR over DOR (Table 1) while AKG116 containing Dmt at the 1 st position and Phe at the 4 th position lacked selectivity in binding assay and displayed higher agonist activity at DOR compared to that at MOR (Table 1) . AKG127 containing Dmt at the 1 st position and Phe(4-F) at the 4 th position showed no selectivity in binding assay. However, it showed higher agonist activity for DOR compared to that at MOR (Table 1) . AKG128 containing Dmt at the 1 st position and NMe-Phe(4-F) at the 4 th position showed no improvement in selectivity. Replacement of Dmt with Tyr at the 1 st position of AKG127 produced the ligand AKG190, which became selective for DOR over MOR in functional assay (Table 1) . We have designed and synthesized novel multifunctional ligands, which are highly potent at the receptors of our interest with desired activities. Ligand AKG115 has shown selectivity at MOR over DOR in binding as well as in functional assays. In vivo study with this ligand is now in progress to evaluate its analgesic activity.
